ArticleAntimicrobial agents and chemotherapy2004

Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.

Giada A Locatelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.